Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...

Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

Shares of Super Micro Computer extend last week’s sharp gains, Snowflake stock is upgraded, and MicroStrategy falls after ...

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

Chicha is a fermented drink made from corn with a long history in South American cultures, but you'll never guess how they ...

The Nigeria Natural Medicine Development Agency (NNMDA) has unveiled plans to train five million Nigerian youths in cassava ...

As we discuss agriculture’s role in a 24-hour economy, we must dispel the myths and misconceptions surrounding it. No, it ...

NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

The Nigerian Senate has advanced efforts to mandate the inclusion of cassava in flour production and its derivatives.

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...